

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandra, Vuginia 22313-1450 www.urpto.gov

FIRST NAMED INVENTOR APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. CONFIRMATION NO. 10/075,175 02/14/2002 Alan M. Peabody PEA13 7325 08/25/2003 7590 McNeil Law Firm, P.A. EXAMINER P.O. Box 10827 DRODGE, JOSEPH W Greenville, SC 29603

ART UNIT

PAPER NUMBER

1723

DATE MAILED: 08/25/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Appl (s)
Office Action Summary		
	10/075,175	PEABODY ET AL.
	Examiner	Art Unit
The MAILING DATE of this communication ap	Joseph W. Drodge	h the correspondence address
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu - Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b). Status	l. .136(a). In no event, however, may a reply within the statutory minimum of thirty d will apply and will expire SIX (6) MONT ate, cause the application to become ABA	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. INDONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on		
,_		ore presention as to the morite is
closed in accordance with the practice unde		
Disposition of Claims		
4) Claim(s) 1-61 is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-61</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/	or election requirement.	
Application Papers		
9) The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	on priority under 35 U.S.C. &	119(a)-(d) or (f)
a) ☐ All b) ☐ Some * c) ☐ None of:	gir priority under oo o.o.o. 3	110(a) (a) 51 (i).
1. Certified copies of the priority documer	nts have been received	
Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the pri	·	•
application from the International B * See the attached detailed Office action for a lis	Bureau (PCT Rule 17.2(a)).	Ť
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).		
a) ☐ The translation of the foreign language p 15)☐ Acknowledgment is made of a claim for domes	* *	
Attachment(s)	· · · ·	
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of In	ummary (PTO-413) Paper No(s) formal Patent Application (PTO-152)

△Application/Control Number: 10/075,175

Art Unit: 1723

NON-FINAL REJECTION

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 3-19, 21-37, 39-42, 44-53 and 55-61 are rejected under 35 U.S.C. 103(a) as being unpatentable over Peabody et al patent 5,643,201 in view of

..Application/Control Number: 10/075,175

Art Unit: 1723

Polaschegg patent 6,280,632 (hereafter abbreviated as "P") and Wamsiedler et al patent 5,808,182 (hereafter abbreviated as "W").

Peabody et al (201) disclose method and apparatus for operating an automated, continuous, peritoneal dialysis system that comprises dialysate preparation component (RO filter 20 and prefilter 10), a fluid circuit for supplying dialysate towards the patient including pump 40 and conduit 41, etc., a flow of spent dialysate to drain (column 10, lines 34-39), inflow line segment (column 7, lines 11-58), dialysate sterilization component including sterilization filter 53 (column 7, lines 55-58), system controller (column 11, lines 2-6) [as in claims 1, 23 and 32], the controller governing filling and draining (column 8, lines 21-64), a dialysate storage vessel 74 or 62 [as in claims 32 and 39], the volume of dialysate accumulated being monitored, see column 7, lines 42-49 [as in claims 8, 29, 32+ and 39+], an outflow line segment 78,84, and as also required by claim 1, a system sterilization component (column 6, lines 65-67).

The claims all differ in requiring means to test the sterilization filter in real time. However, W teaches such testing of a sterilization filter in a dialysis system (hemodialysis), see column 1, line 66-column 2, line 5 and column 5, lines 17-29, etc. as does P in column 2, line 65-column 3, line 8 and column 3, lines 41-49, etc. It would have been obvious to one of ordinary skill in the art to have augmented the Peabody et al system, with such means to test the sterilization filter in real time, as taught by W and P, in order to ensure adequate, safe sterilization of the dialysate that contacts the patient to avoid infection, etc. and to ensure adequate delivery of sufficient volumes of dialysate to the patient.

... Application/Control Number: 10/075,175

Art Unit: 1723

Regarding claims 5, 32+, 42+ and 51, P teaches a secondary sterilization filter in column 5, line 50 as does W starting at column 4, line 24.

Regarding claims 4-14, 16-19, 24-26 and 35-37, the sterilization testing component operating by supplying pressurized air to the filter being tested and monitoring subsequent changes in pressure, etc. are also taught by W in column 5, line 57-column 6, line 4 and P in column 8, lines 18-22 and 50-59. Such means of testing membrane filters have become well known in the filter testing art.

Regarding claim 57, isolation and preliminary purging of the filter being tested is taught by at least P at column 8, lines 36-39.

Regarding claims 20-22 and 59-61, the control of the timing of supplying sterilizing fluid (formaldehyde) by Peabody et al infers use of a controlled valve.

Regarding claims 30 and 31, see Peabody at column 10, lines 11-15 concerning draining and fill cycles.

Regarding claims 28, 33, 34, 40 and 50, use of a discard line segment is taught by P at column 9, line 61.

Regarding claims 41, 52 and 53, the abstract of P teaches that testing of the sterilization filter is conducted just prior to dialysate delivery to the dialysis equipment and start of its operation.

Regarding claims 47 and 48, calculating and monitoring of amounts of dialysate being delivered to the patient and of spent dialysate being drained are taught by Peabody et al in column 7, lines 49-53, column 7, line 63-column 8, line 3 and column 8, lines 17-28.

Application/Control Number: 10/075,175

Art Unit: 1723

Claims 2, 20, 38, 43 and 54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Peabody et al patent 5,643,201 in view of Wamsiedler et al patent 5,808,181 as applied to claims 1, 23, 32, 39 and 49 above, and further in view of Faict et al patent 5,925,011 (hereinafter referred to as "F").

Claim 2 requires proportioning of dialysate from multiple sources so as to adjust its osmality, a feature shown by F column 5, lines 5-11, column 1, lines 18-39, column 4, lines 37-46 and column 8, lines 58-61, etc. It would have been further obvious to one of ordinary skill in the art to have also added such proportioning means to the Peabody et al system, as taught by F, so as to adjust the dialysate to improve the dialysis of waste materials of different types and so as to better ensure safety to the patient by ensuring a pH of the dialysate readily tolerated by organs proximate the peritoneal cavity.

Claims 20, 38, 43 and 54 differ in requiring dialysate delivery systems set up in parallel, see parallel pumping means 12 and 14, etc taught by F. It would have also been obvious to have added such parallel delivery system to the Peabody et al system, as taught by F, to insure consistent delivery of dialysate to the patient even in the event of failure of the pump or a clog, etc. occurring in a single delivery system.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Treu et al patent 6,254,567 teaches complex automation of a peritoneal dialysis system with multiple diverse sensors. DuMoluine et al patent 5,827,820 further discusses osmotic adjustment of peritoneal dialysis fluids.

Art Unit: 1723

Any inquiry concerning this communication from the examiner should be directed to Joseph W. Drodge at 703-308-0403 between the hours of 8:30 and 5:00 Mondays through Fridays.

JWD

August 20, 2003

JOSEPH DRODGE PRIMARY EXAMINER